nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—PSMB10—female reproductive system—rectum cancer	0.0343	0.0543	CbGeAlD
Carfilzomib—PSMB8—seminal vesicle—rectum cancer	0.0342	0.0542	CbGeAlD
Carfilzomib—PSMB5—seminal vesicle—rectum cancer	0.0302	0.0479	CbGeAlD
Carfilzomib—PSMB8—urethra—rectum cancer	0.0271	0.0429	CbGeAlD
Carfilzomib—PSMB1—seminal vesicle—rectum cancer	0.0264	0.0419	CbGeAlD
Carfilzomib—PSMB8—mammalian vulva—rectum cancer	0.0258	0.0409	CbGeAlD
Carfilzomib—PSMB2—seminal vesicle—rectum cancer	0.0258	0.0408	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—rectum cancer	0.0253	0.0401	CbGeAlD
Carfilzomib—PSMB5—urethra—rectum cancer	0.0239	0.0379	CbGeAlD
Carfilzomib—PSMB5—mammalian vulva—rectum cancer	0.0228	0.0361	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—rectum cancer	0.0221	0.035	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—rectum cancer	0.0216	0.0342	CbGeAlD
Carfilzomib—PSMB1—renal system—rectum cancer	0.0213	0.0337	CbGeAlD
Carfilzomib—PSMB1—urethra—rectum cancer	0.0209	0.0331	CbGeAlD
Carfilzomib—PSMB2—renal system—rectum cancer	0.0208	0.0329	CbGeAlD
Carfilzomib—PSMB2—urethra—rectum cancer	0.0204	0.0323	CbGeAlD
Carfilzomib—PSMB10—lymph node—rectum cancer	0.02	0.0318	CbGeAlD
Carfilzomib—PSMB8—vagina—rectum cancer	0.02	0.0317	CbGeAlD
Carfilzomib—PSMB1—mammalian vulva—rectum cancer	0.0199	0.0316	CbGeAlD
Carfilzomib—PSMB2—mammalian vulva—rectum cancer	0.0194	0.0308	CbGeAlD
Carfilzomib—PSMB5—vagina—rectum cancer	0.0176	0.028	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—rectum cancer	0.0171	0.027	CbGeAlD
Carfilzomib—PSMB2—female reproductive system—rectum cancer	0.0166	0.0264	CbGeAlD
Carfilzomib—PSMB1—vagina—rectum cancer	0.0154	0.0244	CbGeAlD
Carfilzomib—PSMB2—vagina—rectum cancer	0.015	0.0238	CbGeAlD
Carfilzomib—PSMB8—lymph node—rectum cancer	0.0129	0.0205	CbGeAlD
Carfilzomib—PSMB5—lymph node—rectum cancer	0.0114	0.0181	CbGeAlD
Carfilzomib—PSMB1—lymph node—rectum cancer	0.00997	0.0158	CbGeAlD
Carfilzomib—PSMB2—lymph node—rectum cancer	0.00973	0.0154	CbGeAlD
Carfilzomib—PSMB10—M Phase—RAB1A—rectum cancer	0.00942	0.0255	CbGpPWpGaD
Carfilzomib—PSMB9—M Phase—RAB1A—rectum cancer	0.00938	0.0254	CbGpPWpGaD
Carfilzomib—PSMB10—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.00864	0.0234	CbGpPWpGaD
Carfilzomib—PSMB9—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.0086	0.0233	CbGpPWpGaD
Carfilzomib—PSMB2—M Phase—RAB1A—rectum cancer	0.00714	0.0194	CbGpPWpGaD
Carfilzomib—PSMB5—M Phase—RAB1A—rectum cancer	0.00714	0.0194	CbGpPWpGaD
Carfilzomib—PSMB1—M Phase—RAB1A—rectum cancer	0.00714	0.0194	CbGpPWpGaD
Carfilzomib—PSMB8—M Phase—RAB1A—rectum cancer	0.00704	0.0191	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.00655	0.0177	CbGpPWpGaD
Carfilzomib—PSMB1—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.00655	0.0177	CbGpPWpGaD
Carfilzomib—PSMB2—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.00655	0.0177	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00646	0.0175	CbGpPWpGaD
Carfilzomib—PSMB8—Mitotic M-M/G1 phases—RAB1A—rectum cancer	0.00645	0.0175	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00643	0.0174	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—RAB1A—rectum cancer	0.00578	0.0157	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—RAB1A—rectum cancer	0.00575	0.0156	CbGpPWpGaD
Carfilzomib—PSMB10—G1/S Transition—TYMS—rectum cancer	0.00542	0.0147	CbGpPWpGaD
Carfilzomib—PSMB9—G1/S Transition—TYMS—rectum cancer	0.0054	0.0146	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.0049	0.0133	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.0049	0.0133	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.0049	0.0133	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—RAB1A—rectum cancer	0.00483	0.0131	CbGpPWpGaD
Carfilzomib—PSMB10—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00457	0.0124	CbGpPWpGaD
Carfilzomib—PSMB9—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00455	0.0123	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—RAB1A—rectum cancer	0.00438	0.0119	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—RAB1A—rectum cancer	0.00438	0.0119	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—RAB1A—rectum cancer	0.00438	0.0119	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—RAB1A—rectum cancer	0.00432	0.0117	CbGpPWpGaD
Carfilzomib—PSMB2—G1/S Transition—TYMS—rectum cancer	0.00411	0.0111	CbGpPWpGaD
Carfilzomib—PSMB1—G1/S Transition—TYMS—rectum cancer	0.00411	0.0111	CbGpPWpGaD
Carfilzomib—PSMB5—G1/S Transition—TYMS—rectum cancer	0.00411	0.0111	CbGpPWpGaD
Carfilzomib—PSMB8—G1/S Transition—TYMS—rectum cancer	0.00405	0.011	CbGpPWpGaD
Carfilzomib—ABCB1—seminal vesicle—rectum cancer	0.00394	0.00624	CbGeAlD
Carfilzomib—PSMB2—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00346	0.00939	CbGpPWpGaD
Carfilzomib—PSMB5—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00346	0.00939	CbGpPWpGaD
Carfilzomib—PSMB1—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00346	0.00939	CbGpPWpGaD
Carfilzomib—ABCB1—epithelium—rectum cancer	0.00342	0.00542	CbGeAlD
Carfilzomib—PSMB8—Mitotic G1-G1/S phases—TYMS—rectum cancer	0.00342	0.00926	CbGpPWpGaD
Carfilzomib—PSMB10—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00336	0.0091	CbGpPWpGaD
Carfilzomib—PSMB9—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00334	0.00905	CbGpPWpGaD
Carfilzomib—PSMB10—Stabilization of p53—TP53—rectum cancer	0.0033	0.00895	CbGpPWpGaD
Carfilzomib—PSMB9—Stabilization of p53—TP53—rectum cancer	0.00329	0.00891	CbGpPWpGaD
Carfilzomib—ABCB1—renal system—rectum cancer	0.00317	0.00503	CbGeAlD
Carfilzomib—ABCB1—urethra—rectum cancer	0.00312	0.00494	CbGeAlD
Carfilzomib—PSMB10—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00307	0.00831	CbGpPWpGaD
Carfilzomib—PSMB9—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00305	0.00827	CbGpPWpGaD
Carfilzomib—ABCB1—mammalian vulva—rectum cancer	0.00297	0.0047	CbGeAlD
Carfilzomib—PSMB10—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00294	0.00797	CbGpPWpGaD
Carfilzomib—PSMB9—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00293	0.00793	CbGpPWpGaD
Carfilzomib—PSMB5—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00254	0.00689	CbGpPWpGaD
Carfilzomib—PSMB1—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00254	0.00689	CbGpPWpGaD
Carfilzomib—PSMB2—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00254	0.00689	CbGpPWpGaD
Carfilzomib—ABCB1—female reproductive system—rectum cancer	0.00254	0.00403	CbGeAlD
Carfilzomib—PSMB8—Autodegradation of the E3 ubiquitin ligase COP1—TP53—rectum cancer	0.00251	0.0068	CbGpPWpGaD
Carfilzomib—PSMB2—Stabilization of p53—TP53—rectum cancer	0.0025	0.00679	CbGpPWpGaD
Carfilzomib—PSMB5—Stabilization of p53—TP53—rectum cancer	0.0025	0.00679	CbGpPWpGaD
Carfilzomib—PSMB1—Stabilization of p53—TP53—rectum cancer	0.0025	0.00679	CbGpPWpGaD
Carfilzomib—PSMB8—Stabilization of p53—TP53—rectum cancer	0.00247	0.00669	CbGpPWpGaD
Carfilzomib—PSMB2—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00232	0.0063	CbGpPWpGaD
Carfilzomib—PSMB1—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00232	0.0063	CbGpPWpGaD
Carfilzomib—PSMB5—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00232	0.0063	CbGpPWpGaD
Carfilzomib—ABCB1—vagina—rectum cancer	0.0023	0.00364	CbGeAlD
Carfilzomib—PSMB8—p53-Dependent G1 DNA Damage Response—TP53—rectum cancer	0.00229	0.00621	CbGpPWpGaD
Carfilzomib—PSMB5—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00223	0.00604	CbGpPWpGaD
Carfilzomib—PSMB1—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00223	0.00604	CbGpPWpGaD
Carfilzomib—PSMB2—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.00223	0.00604	CbGpPWpGaD
Carfilzomib—PSMB8—G1/S DNA Damage Checkpoints—TP53—rectum cancer	0.0022	0.00595	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle Checkpoints—TP53—rectum cancer	0.0017	0.00461	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle Checkpoints—TP53—rectum cancer	0.00169	0.00459	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00168	0.00454	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00167	0.00453	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00167	0.00452	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00166	0.00451	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TYMS—rectum cancer	0.0015	0.00406	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TYMS—rectum cancer	0.00149	0.00404	CbGpPWpGaD
Carfilzomib—ABCB1—lymph node—rectum cancer	0.00149	0.00236	CbGeAlD
Carfilzomib—PSMB10—B Cell Activation—NRAS—rectum cancer	0.00148	0.004	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—NRAS—rectum cancer	0.00147	0.00398	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00144	0.0039	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00143	0.00388	CbGpPWpGaD
Carfilzomib—PSMB10—Apoptosis—TP53—rectum cancer	0.00136	0.00368	CbGpPWpGaD
Carfilzomib—PSMB9—Apoptosis—TP53—rectum cancer	0.00135	0.00366	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle Checkpoints—TP53—rectum cancer	0.00129	0.00349	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle Checkpoints—TP53—rectum cancer	0.00129	0.00349	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle Checkpoints—TP53—rectum cancer	0.00129	0.00349	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—KRAS—rectum cancer	0.00127	0.00345	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00127	0.00344	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00127	0.00344	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00127	0.00344	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle Checkpoints—TP53—rectum cancer	0.00127	0.00344	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00127	0.00343	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00127	0.00343	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00127	0.00343	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—KRAS—rectum cancer	0.00126	0.00343	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—TYMS—rectum cancer	0.00125	0.0034	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00125	0.00339	CbGpPWpGaD
Carfilzomib—PSMB10—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00122	0.00332	CbGpPWpGaD
Carfilzomib—PSMB9—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00122	0.0033	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TYMS—rectum cancer	0.00114	0.00308	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TYMS—rectum cancer	0.00114	0.00308	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TYMS—rectum cancer	0.00114	0.00308	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TYMS—rectum cancer	0.00112	0.00304	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—SLC14A2—rectum cancer	0.00112	0.00304	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—NRAS—rectum cancer	0.00112	0.00303	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—NRAS—rectum cancer	0.00112	0.00303	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—NRAS—rectum cancer	0.00112	0.00303	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—NRAS—rectum cancer	0.0011	0.00299	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00109	0.00296	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00109	0.00296	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00109	0.00296	CbGpPWpGaD
Carfilzomib—PSMB10—B Cell Activation—HRAS—rectum cancer	0.00108	0.00293	CbGpPWpGaD
Carfilzomib—PSMB9—B Cell Activation—HRAS—rectum cancer	0.00108	0.00291	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00108	0.00291	CbGpPWpGaD
Carfilzomib—PSMB1—Apoptosis—TP53—rectum cancer	0.00103	0.00279	CbGpPWpGaD
Carfilzomib—PSMB5—Apoptosis—TP53—rectum cancer	0.00103	0.00279	CbGpPWpGaD
Carfilzomib—PSMB2—Apoptosis—TP53—rectum cancer	0.00103	0.00279	CbGpPWpGaD
Carfilzomib—PSMB8—Apoptosis—TP53—rectum cancer	0.00101	0.00275	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—KRAS—rectum cancer	0.000963	0.00261	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—KRAS—rectum cancer	0.000963	0.00261	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—KRAS—rectum cancer	0.000963	0.00261	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—KRAS—rectum cancer	0.00095	0.00257	CbGpPWpGaD
Carfilzomib—PSMB5—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000927	0.00251	CbGpPWpGaD
Carfilzomib—PSMB1—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000927	0.00251	CbGpPWpGaD
Carfilzomib—PSMB2—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000927	0.00251	CbGpPWpGaD
Carfilzomib—PSMB8—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.000914	0.00248	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—NRAS—rectum cancer	0.000826	0.00224	CbGpPWpGaD
Carfilzomib—PSMB2—B Cell Activation—HRAS—rectum cancer	0.000819	0.00222	CbGpPWpGaD
Carfilzomib—PSMB5—B Cell Activation—HRAS—rectum cancer	0.000819	0.00222	CbGpPWpGaD
Carfilzomib—PSMB1—B Cell Activation—HRAS—rectum cancer	0.000819	0.00222	CbGpPWpGaD
Carfilzomib—PSMB8—B Cell Activation—HRAS—rectum cancer	0.000807	0.00219	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.000772	0.00209	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—KRAS—rectum cancer	0.000711	0.00193	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—TYMS—rectum cancer	0.000644	0.00175	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—TYMS—rectum cancer	0.000641	0.00174	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HRAS—rectum cancer	0.000604	0.00164	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—NRAS—rectum cancer	0.000595	0.00161	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—NRAS—rectum cancer	0.000593	0.00161	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—KRAS—rectum cancer	0.000512	0.00139	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—KRAS—rectum cancer	0.00051	0.00138	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—rectum cancer	0.000497	0.00135	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—rectum cancer	0.000495	0.00134	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—TYMS—rectum cancer	0.000488	0.00132	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—TYMS—rectum cancer	0.000488	0.00132	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—TYMS—rectum cancer	0.000488	0.00132	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—TYMS—rectum cancer	0.000481	0.0013	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—NRAS—rectum cancer	0.000451	0.00122	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—NRAS—rectum cancer	0.000451	0.00122	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—NRAS—rectum cancer	0.000451	0.00122	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—NRAS—rectum cancer	0.000445	0.00121	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—HRAS—rectum cancer	0.000436	0.00118	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HRAS—rectum cancer	0.000433	0.00117	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—KRAS—rectum cancer	0.000388	0.00105	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—KRAS—rectum cancer	0.000388	0.00105	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—KRAS—rectum cancer	0.000388	0.00105	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—KRAS—rectum cancer	0.000383	0.00104	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—rectum cancer	0.000377	0.00102	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—rectum cancer	0.000377	0.00102	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—rectum cancer	0.000377	0.00102	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—rectum cancer	0.000371	0.00101	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NRAS—rectum cancer	0.000361	0.000979	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NRAS—rectum cancer	0.000359	0.000974	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NRAS—rectum cancer	0.000333	0.000904	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NRAS—rectum cancer	0.000332	0.000899	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—rectum cancer	0.00033	0.000895	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—rectum cancer	0.00033	0.000895	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—rectum cancer	0.00033	0.000895	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—rectum cancer	0.000325	0.000882	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KRAS—rectum cancer	0.000311	0.000842	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KRAS—rectum cancer	0.000309	0.000838	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.000288	0.000781	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—rectum cancer	0.000287	0.000778	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—rectum cancer	0.000286	0.000774	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—rectum cancer	0.000274	0.000742	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—rectum cancer	0.000274	0.000742	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—rectum cancer	0.000274	0.000742	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—rectum cancer	0.00027	0.000731	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—rectum cancer	0.000264	0.000716	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—rectum cancer	0.000263	0.000713	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.000256	0.000694	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—rectum cancer	0.000253	0.000685	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—rectum cancer	0.000253	0.000685	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—rectum cancer	0.000253	0.000685	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—rectum cancer	0.000249	0.000675	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—rectum cancer	0.000244	0.000661	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—rectum cancer	0.000243	0.000658	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—rectum cancer	0.000236	0.000638	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—rectum cancer	0.000236	0.000638	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—rectum cancer	0.000236	0.000638	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—rectum cancer	0.000233	0.000633	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—rectum cancer	0.000232	0.00063	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—rectum cancer	0.000232	0.000629	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—rectum cancer	0.000217	0.000589	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—rectum cancer	0.000217	0.000589	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—rectum cancer	0.000217	0.000589	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—rectum cancer	0.000214	0.000581	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—rectum cancer	0.000201	0.000545	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—rectum cancer	0.0002	0.000543	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—rectum cancer	0.0002	0.000543	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—rectum cancer	0.0002	0.000543	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—rectum cancer	0.0002	0.000542	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—rectum cancer	0.000197	0.000535	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—rectum cancer	0.000185	0.000501	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—rectum cancer	0.000185	0.000501	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—rectum cancer	0.000185	0.000501	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—rectum cancer	0.000182	0.000494	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—rectum cancer	0.000179	0.000484	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—rectum cancer	0.000178	0.000482	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—rectum cancer	0.000177	0.00048	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—rectum cancer	0.000177	0.00048	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—rectum cancer	0.000177	0.00048	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—rectum cancer	0.000174	0.000473	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—rectum cancer	0.000171	0.000463	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—rectum cancer	0.00017	0.000461	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—rectum cancer	0.000152	0.000413	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—rectum cancer	0.000152	0.000413	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—rectum cancer	0.000152	0.000413	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—rectum cancer	0.00015	0.000407	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—rectum cancer	0.000144	0.000389	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—rectum cancer	0.000135	0.000367	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—rectum cancer	0.000135	0.000367	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—rectum cancer	0.000135	0.000367	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—rectum cancer	0.000133	0.000362	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—rectum cancer	0.000129	0.000351	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—rectum cancer	0.000129	0.000351	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—rectum cancer	0.000129	0.000351	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—rectum cancer	0.000128	0.000346	CbGpPWpGaD
